Anti-ischemic cardioprotective effects and influence on disturbed microcirculation regress of the blocker AT1-receptors of angiotensin II candesartan cylecsitil combined with beta1-adrenoblocker nebivolol in patients having ischemic heart failure associated with the 2nd type diabetes mellitus

Results of the study of antiischemic, cardioprotective, hemodynamic and metabolic effects as well as influence on disturbed microcirculation regress of the blocker AT1-receptors of angiotensin II candesartan cylecsitil combined with b1-adrenoblocker nebivolol in the secondary prevention of chronic heart failure in patients having ischemic heat failure associated with the 2-nd type diabetes mellitus are given in the article. The study included 20 patients aged 57,6±3,1 years. The study results showed high anti-ichemic and anti-hypertensive efficacy of combined therapy of AT1- receptors A II candesartan in a dose of 8-16 mg/day combined with b1-adrenoblocker nebivolol in a dose of 2,5-5 mg/day during 4-week therapy course and revealed significantly increased endothelium-dependent vasodilation in response to maximum blood flow during the test with regional hyperemia which points to improved endothelial function.